All In Biotech

Drug Trial Radar · NCT07743541

Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy

A Multicenter Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the NaPi2B Antibody-Drug Conjugate TUB-040 in Patients With Recurrent or Progressive Uterine Endometrial Cancer After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with recurrent or progressive uterine endometrial cancer after platinum-based chemotherapy and immune checkpoint inhibitor therapy. The primary objectives of Phase 1 of this study are to determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). The primary objective of Phase 2 of this study is to evaluate the efficacy of TUB-040 monotherapy at the RP2D in endometrial cancer.

Conditions

  • Uterine Endometrial Cancer

Interventions

  • TUB-040 - Dose escalationDrug

    TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle.

  • TUB-040 - RP2DDrug

    TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle. Dose based on the RP2D

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years
  2. Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to 3 years
  3. Phase 2: Overall Response Rate (ORR)Time frame: Up to 3 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • START Los Angeles

    Los Angeles, California

  • START New Jersey

    East Brunswick, New Jersey

  • START New York-Long Island

    Lake Success, New York

  • START Mountain Region, LLC

    West Valley City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.